Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Brentuximab Vedotin
100%
Advanced Urothelial Cancer
51%
Indoleamine 2,3-dioxygenase 1 (IDO1)
48%
Urothelial Cancer
48%
Tumor
46%
Overall Survival
45%
Dendritic Cells
42%
Enfortumab
39%
T Cells
36%
Urothelial Carcinoma
31%
Tumor Expression
29%
Non-muscle Invasive Bladder Cancer (NMIBC)
28%
Bladder Cancer
28%
B Cells
28%
Nectin-4
27%
Immune Checkpoint Inhibitors
26%
Cutaneous Toxicity
26%
Immune Checkpoint Therapy
25%
Sarcomatoid
24%
Single-center Experience
24%
Sarcomatoid Urothelial Carcinoma
24%
Gene Therapy
24%
Durvalumab
24%
Antibody-drug Conjugate
24%
Neoadjuvant
23%
Gene Signature
21%
Cisplatin
18%
Chronic Inflammation
18%
Cisplatin Eligible
17%
Response Rate
16%
Sacituzumab Govitecan
16%
In Cancer
15%
Atezolizumab
14%
Radical Cystectomy
14%
Radiological Response
14%
Immune Privilege
13%
Adenoviral
13%
Programmed Death-ligand 1 (PD-L1)
13%
Interferon-α (IFN-α)
13%
Tumor Microenvironment
13%
High Risk
13%
95% Confidence Interval
13%
Previously Treated
13%
Bacillus Calmette-Guérin Unresponsive
13%
Interleukin-6
13%
Bladder Cancer Model
13%
Cisplatin-ineligible
13%
Bladder Cancer Therapy
13%
Regulatory T Cells
12%
Hazard Ratio
12%
Medicine and Dentistry
Enfortumab Vedotin
88%
Urothelial Cancer
87%
Overall Survival
35%
Transitional Cell Carcinoma
30%
Enfortumab
27%
Skin Toxicity
26%
Immune Checkpoint Inhibitor
25%
Cisplatin
25%
Cystectomy
25%
Sarcomatoid
24%
Durvalumab
24%
Diseases
23%
Antibody-Drug Conjugate
20%
Muscle Invasive Bladder Cancer
17%
Neoplasm
16%
Retrospective Study
15%
Sacituzumab Govitecan
14%
Bladder
14%
Histology
12%
B Cell
12%
Mycobacterium Bovis BCG
12%
Non Muscle Invasive Bladder Cancer
12%
Squamous Cell Carcinoma
12%
Cancer Research
12%
External Beam Radiotherapy
12%
Gemcitabine
12%
Antigen Presenting Cell
12%
Sorafenib
12%
Cancer Therapy
12%
Health Care Cost
12%
Protein Kinase B
12%
Differentiated Thyroid Cancer
12%
Hazard Ratio
11%
Tumor
11%
Platinum
8%
Progression Free Survival
7%
Monotherapy
7%
Chemotherapy
7%
Nectin
6%
Biological Marker
6%
Programmed Death-Ligand 1
6%
Neoadjuvant Chemotherapy
5%
Combination Therapy
5%
Pembrolizumab
5%
Body Mass Index
5%
Immunology and Microbiology
T Cell
50%
Indoleamine 2,3-dioxygenase
48%
Immunotherapy
43%
Dendritic Cell
42%
Regulatory T Cell
27%
interferon
25%
Immune Checkpoint Inhibitor
25%
Overall Survival
25%
Enfortumab Vedotin
24%
Programmed Death-Ligand 1
23%
RNA Sequence
19%
Inflammation
18%
Muscle
18%
B Cell
17%
Gene Expression Assay
16%
Cytotoxic T-Cell
14%
Macrophage
14%
Immune Privilege
13%
Atezolizumab
13%
Innate Lymphoid Cell
12%
Interferon Alfa
12%
Neoantigen
12%
Tumor Immunogenicity
12%
Nadofaragene Firadenovec
12%
Autoantibodies
12%
Enfortumab
12%
Pretreatment
12%
Antigen-Presenting Cell
12%
Thyroid
12%
Sorafenib
12%
Chronic Granulomatous Disease
12%
CD163
12%
Plasmacytoid Dendritic Cell
11%
Cytokine
10%
Acetate
10%
TLR9
10%
Cell Death
10%
Upregulation
10%
Immune Tolerance
8%
Stroma
8%
Adenoviridae
8%
Tumor Cell
8%
Transcription Factor GATA 3
8%
Immunosuppressive Drug
7%
Transcriptome
7%
Fibroblast
7%
Autoimmunity
6%
CD19
6%
Signal Transduction
5%
Immunocompetent Cell
5%